In 2022, OBI Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, OBI Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2022 |
|---|---|
Total Scope 1 | 25.331a |
Total Scope 2 | |
Unspecified Calculation Method | 552.311a |
Total Scope 3 | 168.562a |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 165.2269a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2022, the total operational greenhouse gas (GHG) emissions of OBI Pharma amounted to 577.641 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2022, the total Scope 1 emissions of OBI Pharma were 25.331 metric tons of CO₂ equivalent (tCO₂e).a
In 2022, OBI Pharma reported Scope 2 greenhouse gas (GHG) emissions of 552.311 tCO₂e without specifying the calculation method.a
In 2022, OBI Pharma reported its Scope 2 emissions using an unspecified methodology.a
In 2022, OBI Pharma reported 168.562 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2022 disclosure of OBI Pharma includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in , demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2022, OBI Pharma reported total Scope 3 emissions of 168.562 metric tons of CO₂ equivalent (tCO₂e).a
In 2022, OBI Pharma reported Scope 1 greenhouse gas (GHG) emissions of 25.331 tCO₂e and total revenues of USD 0 millions. This translates into an emissions intensity of 165.23 tCO₂e per millions USD.a
In 2022, OBI Pharma reported a Scope 1 emissions intensity of 165.23 tCO₂e per millions USD. Compared to the peer group median of 4.35, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2022, OBI Pharma ranked 23 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places OBI Pharma among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2022, OBI Pharma reported a total carbon footprint of 746.203 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions.a
The largest contributor to OBI Pharma's total carbon footprint was Scope 2 emissions, accounting for 74.02% of the company's total carbon footprint, followed by Scope 3 emissions at 22.59%.a